| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Procodazole inhibits the 8His-tagged Pin1 PPIase domain (45-163) with an IC50 of 740. It is a carbonic anhydrase inhibitor. Its primary mechanism is as an immunoprotective agent, enhancing the immune response.
|
|---|---|
| ln Vitro |
In cell-free systems, Procodazole's activity is assessed by its ability to inhibit Pin1 PPIase or carbonic anhydrase. Enzyme inhibition assays are used to determine its IC50. Its binding to these enzymes is characterized. In vitro, Procodazole exhibits antibacterial and antiviral activities. It also has antiparasitic activity. It acts as a potentiator, enhancing immune responses in cell-based assays.
|
| ln Vivo |
In vivo, Procodazole is an orally active immunoprotective agent. It protects against viral and bacterial infections in animal models. It also exhibits antitumor activity. It is used as an additive in vaccines to enhance their efficacy.
|
| Enzyme Assay |
Enzyme inhibition assays are performed using purified Pin1 PPIase or carbonic anhydrase. The compound is incubated with the enzyme and a substrate. The inhibition of enzyme activity is measured to determine the IC50.
|
| Cell Assay |
Cells are treated with Procodazole, and its effects on immune cell function are assessed. This may involve measuring cytokine production or the activation of immune cells. Its antiparasitic activity is assessed in cell-based assays.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of infection. Animals are infected with a pathogen and treated with Procodazole. The reduction in mortality or pathogen load is measured. Its immunomodulatory effects are assessed by analyzing immune cell populations and cytokine levels.
|
| ADME/Pharmacokinetics |
Procodazole is orally active. Its pharmacokinetic properties are not well-documented, but its oral bioavailability suggests it is absorbed from the gastrointestinal tract. Its metabolism and excretion are not well-characterized.
|
| Toxicity/Toxicokinetics |
Procodazole is generally considered safe for research use. Its toxicity profile is not well-documented. As an immunomodulatory agent, its long-term safety and potential for immune-related side effects require further investigation.
|
| Additional Infomation |
Propidazol belongs to the benzimidazole class of compounds.
Procodazole is a research compound with potential applications as an immunoprotective agent and vaccine adjuvant. It is not an approved drug but has been studied for its ability to enhance immune responses against infections and cancer. |
| Molecular Formula |
C10H10N2O2
|
|---|---|
| Molecular Weight |
190.1986
|
| Exact Mass |
190.074
|
| CAS # |
23249-97-0
|
| PubChem CID |
65708
|
| Appearance |
White to off-white solid powder
|
| Density |
1.367 g/cm3
|
| Boiling Point |
497.9ºC at 760 mmHg
|
| Melting Point |
229-231 °C (dec.)(lit.)
|
| Flash Point |
254.9ºC
|
| Vapour Pressure |
9.84E-11mmHg at 25°C
|
| LogP |
1.58
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
14
|
| Complexity |
220
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(O)CCC1=NC2=CC=CC=C2N1
|
| InChi Key |
XYWJNTOURDMTPI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H10N2O2/c13-10(14)6-5-9-11-7-3-1-2-4-8(7)12-9/h1-4H,5-6H2,(H,11,12)(H,13,14)
|
| Chemical Name |
3-(1H-benzimidazol-2-yl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~262.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.14 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (13.14 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2576 mL | 26.2881 mL | 52.5762 mL | |
| 5 mM | 1.0515 mL | 5.2576 mL | 10.5152 mL | |
| 10 mM | 0.5258 mL | 2.6288 mL | 5.2576 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
